Delova Biotech
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Developing next-generation biologic therapies, including bispecifics and ADCs, for oncology.
Oncology
Technology Platform
Antibody engineering platform for the discovery and development of bispecific antibodies and antibody-drug conjugates (ADCs) against cancer targets.
Opportunities
Riding the global wave of ADC and bispecific antibody innovation, with potential for lucrative licensing deals with global pharma.
Risk Factors
Technical complexity of manufacturing novel biologics and the clinical risk of novel mechanisms, including potential for severe adverse events like cytokine release syndrome.
Competitive Landscape
Competes in the highly active bispecific and ADC arena, where technological differentiation and clinical execution are critical to securing partnerships.